A new stroke prevention drug developed by Bayer and Johnson & Johnson proved a safe alternative to the standard treatment, lifting their chances of entering a $12 billion plus market, the German drug company said.
A late-stage study called Rocket-AF showed that the Xarelto pill was as good as the established warfarin pill at reducing the risk of strokes due to a form of irregular heartbeat that is common among the elderly, Bayer said on Sunday. Get the full story »
